Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.53 |
| ▸ | NAPEPLD | Q6IQ20 | 9/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926309 | 0.81 | AKT1 (0.54) | PIK3CANAPEPLD | |
| SCHEMBL3116640 | 0.80 | PIK3CA (0.55) | PIK3CANAPEPLD | |
| SCHEMBL3106073 | 0.80 | PIK3CA (0.62) | PIK3CANAPEPLD | |
| SCHEMBL11926308 | 0.76 | KDM4E (0.43) | NAPEPLD | |
| SCHEMBL13439746 | 0.76 | NAPEPLD (0.43) | NAPEPLD | |
| SCHEMBL23299902 | 0.73 | NAPEPLD (0.43) | PIK3CANAPEPLD | |
| SCHEMBL3108475 | 0.72 | KMO (0.50) | PIK3CAKMO | |
| SCHEMBL425720 | 0.71 | KMO (0.57) | PIK3CAKMO | |
| SCHEMBL13257330 | 0.71 | PIK3CA (0.87) | PIK3CA | |
| SCHEMBL3112884 | 0.70 | PIK3CA (0.52) | PIK3CANAPEPLD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | PIK3CA 2810/4885NAPEPLD 1303/4885KMO 1707/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | PIK3CA 2810/4885NAPEPLD 1303/4885KMO 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.